Physiomics PLC
Company Profile
Business description
Physiomics PLC is engaged in providing consulting and contract research services to biopharmaceutical companies and research institutes in the areas of outsourced Modelling and Simulation (Quantitative Pharmacology),Biometrics (Biostatistics, Statistical Programming and Data Management) and Data Science, using a combination of industry standard technologies and its own proprietary technology platform, Virtual Tumour. It helps drug developers accelerate the development of their novel therapies towards market by supporting them to gain insights from their data that will inform their research decisions and support regulatory review. It has single operating segment. Its solutions are Mechanism of Action Modelling, Exposure Response Modelling, Translational Modelling, PBPK Modelling, etc.
Contact
99 Park Drive
Milton Park Innovation Centre, Milton Park
Oxfordshire
AbingdonOX14 4RY
GBRT: +44 1235841575
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
10
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
stocks
Downgrade for ASX listed fund manager as redemptions pile on
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,940.40 | 100.00 | 1.13% |
| CAC 40 | 7,956.70 | 22.00 | 0.28% |
| DAX 40 | 25,622.61 | 239.99 | 0.95% |
| Dow JONES (US) | 52,002.41 | 175.28 | -0.34% |
| FTSE 100 | 10,881.90 | 41.55 | 0.38% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,140.03 | 572.99 | -2.14% |
| Nikkei 225 | 65,324.29 | 898.34 | 1.39% |
| NZX 50 Index | 13,753.73 | 79.07 | -0.57% |
| S&P 500 | 7,659.44 | 84.62 | -1.09% |
| S&P/ASX 200 | 8,806.70 | 87.00 | 1.00% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |